A focused discussion of emerging evidence for improving care and clinical outcomes in adult and pediatric patients with gastrointestinal/hepatic/pancreatic (GI) sequelae of Cystic Fibrosis (CF), particularly regarding concerted treatment and screening initiatives that will come into play for more CF patients with progressively rising life expectancy outcomes.
Evaluate available screening strategies for evolving CF GI diseases.
Discuss how structured Quality Improvement processes can strengthen the patient/provider partnership in CF Nutrition.
Examine strategies to optimize pancreatic enzyme supplementation and efficacy in CF patients.
Consider potential biomarkers and therapeutic pathways for future treatment of CF GI diseases.